EA200100925A1 - Применение глицинбетаина в качестве антитромботического средства - Google Patents

Применение глицинбетаина в качестве антитромботического средства

Info

Publication number
EA200100925A1
EA200100925A1 EA200100925A EA200100925A EA200100925A1 EA 200100925 A1 EA200100925 A1 EA 200100925A1 EA 200100925 A EA200100925 A EA 200100925A EA 200100925 A EA200100925 A EA 200100925A EA 200100925 A1 EA200100925 A1 EA 200100925A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glycine betaine
relates
therapeutic
blood clots
glycinbetaine
Prior art date
Application number
EA200100925A
Other languages
English (en)
Other versions
EA004047B1 (ru
Inventor
Яллал Мессадек
Original Assignee
Яллал Мессадек
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Яллал Мессадек filed Critical Яллал Мессадек
Publication of EA200100925A1 publication Critical patent/EA200100925A1/ru
Publication of EA004047B1 publication Critical patent/EA004047B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В заявке описано применение глицинбетаина для лечения физиопатологических сосудистых болезней. Изобретение относится к применению глицинбетаина в качестве лечебного и профилактического средства при патогенезе тромбоэмболических и гемостатических болезней артериального или венозного происхождения. Глицинбетаин обладает профилактической активностью, предупреждая образование тромбов, и лечебной активностью, ингибируя пролиферацию тромбов путем их разрушения. Изобретение отличается тем, что применение глицинбетаина не связано с каким-либо риском возникновения кровотечения или развитием аллергии в отличие от применяемых в настоящее время соединений и методов лечения. Изобретение также относится к применению глицинбетаина в качестве антикоагулянта для консервации крови.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100925A 1999-03-02 2000-03-01 Применение глицинбетаина в качестве антитромботического средства EA004047B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9900144A BE1012495A3 (fr) 1999-03-02 1999-03-02 La glycine-betaine pour son usage antithrombotique.
PCT/BE2000/000021 WO2000051596A1 (fr) 1999-03-02 2000-03-01 La glycine betaïne pour son usage antithrombotique

Publications (2)

Publication Number Publication Date
EA200100925A1 true EA200100925A1 (ru) 2002-04-25
EA004047B1 EA004047B1 (ru) 2003-12-25

Family

ID=3891794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100925A EA004047B1 (ru) 1999-03-02 2000-03-01 Применение глицинбетаина в качестве антитромботического средства

Country Status (20)

Country Link
US (1) US6855734B2 (ru)
EP (1) EP1156796B1 (ru)
JP (1) JP2002538113A (ru)
KR (1) KR100767270B1 (ru)
CN (1) CN1194681C (ru)
AT (1) ATE311226T1 (ru)
AU (1) AU2897900A (ru)
BE (1) BE1012495A3 (ru)
BR (1) BR0008631A (ru)
CA (1) CA2362558C (ru)
DE (1) DE60024415T2 (ru)
EA (1) EA004047B1 (ru)
ES (1) ES2254144T3 (ru)
HK (1) HK1044276B (ru)
HU (1) HUP0105397A3 (ru)
IL (1) IL145068A0 (ru)
MX (1) MXPA01008426A (ru)
NZ (1) NZ513905A (ru)
PL (1) PL204560B1 (ru)
WO (1) WO2000051596A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
DK1408949T3 (da) * 2001-02-05 2008-04-28 Jallal Messadek Glycinbetain og dets brugområde for opfindelsen
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
JP2005518453A (ja) * 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2002343174A1 (en) * 2002-11-25 2004-06-18 Rachid Ennamany Betaine and salicylic acid compositions
US8697679B2 (en) 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
CA2575760A1 (en) * 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
CN101180257A (zh) 2005-02-24 2008-05-14 扩散药品有限公司 反式类胡萝卜素、其合成、制剂和用途
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
EA200970944A1 (ru) 2007-04-13 2010-06-30 Диффьюжн Фармасьютикалз Ллс Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
CA2703946A1 (en) * 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
AU2010263245A1 (en) 2009-06-22 2012-01-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
CN103124498A (zh) 2010-06-02 2013-05-29 扩散药品有限公司 双极性反式类胡萝卜素的口服制剂
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用
CN109342606B (zh) * 2018-12-05 2021-11-02 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种水产品中甘氨酸甜菜碱的检测方法
US11285349B1 (en) * 2019-10-07 2022-03-29 TFS Holdings, LLC Sprinkler system antifreeze compositions and methods
CN111505131B (zh) * 2020-01-02 2023-03-31 东莞东华医院有限公司 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980277A (en) * 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
EP0347864A3 (en) * 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Anti-atherogenic agents
WO1995015750A1 (en) * 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11727B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6162852A (en) 1996-12-13 2000-12-19 Isolyser Company, Inc. Degradable polymers

Also Published As

Publication number Publication date
ATE311226T1 (de) 2005-12-15
US6855734B2 (en) 2005-02-15
PL204560B1 (pl) 2010-01-29
ES2254144T3 (es) 2006-06-16
CA2362558A1 (fr) 2000-09-08
NZ513905A (en) 2001-09-28
CA2362558C (fr) 2009-06-02
KR20020021369A (ko) 2002-03-20
DE60024415T2 (de) 2006-09-21
DE60024415D1 (de) 2006-01-05
HK1044276B (zh) 2006-12-22
CN1194681C (zh) 2005-03-30
US20020065320A1 (en) 2002-05-30
EA004047B1 (ru) 2003-12-25
HK1044276A1 (en) 2002-10-18
JP2002538113A (ja) 2002-11-12
AU2897900A (en) 2000-09-21
KR100767270B1 (ko) 2007-10-17
HUP0105397A3 (en) 2003-03-28
WO2000051596A1 (fr) 2000-09-08
EP1156796B1 (fr) 2005-11-30
MXPA01008426A (es) 2003-06-06
EP1156796A1 (fr) 2001-11-28
BE1012495A3 (fr) 2000-11-07
WO2000051596A9 (fr) 2001-10-11
IL145068A0 (en) 2002-06-30
PL350408A1 (en) 2002-12-02
HUP0105397A2 (hu) 2002-05-29
CN1342071A (zh) 2002-03-27
BR0008631A (pt) 2002-02-13

Similar Documents

Publication Publication Date Title
EA200100925A1 (ru) Применение глицинбетаина в качестве антитромботического средства
CL2004000376A1 (es) Compuestos derivados de fenil propil amidas n-(aminoiminometil o aminometil) susttiuidas; compuestos intermediarios; composicion farmaceutica; y su uso para tratar un efecto patologico de la trombina, como trastornos tromboticos venosos o arteriales.
EA200401240A1 (ru) Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов
WO2010065077A3 (en) Antagonists of il-6 to prevent or treat thrombosis
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
Carrijo et al. Biological properties of the venom from the scorpionfish (Scorpaena plumieri) and purification of a gelatinolytic protease
CY1113705T1 (el) Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
DK0558529T3 (da) Farmaceutisk præparat til behandling af forlænget koagulationstid
EA200300849A1 (ru) Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
AU9576901A (en) Preparation for the relief of disease
WO2003007921A3 (en) Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
EA200000059A1 (ru) Блокада cd154 как лечение синдрома ингибирования терапевтических белков
EP1544214A4 (en) Non-neutralizing anti-aPC antibodies
Mahadeswaraswamy et al. Local tissue destruction and procoagulation properties of Echis carinatus venom: inhibition by Vitis vinifera seed methanol extract
Hasegawa Clinical assessment of warfarin therapy in patients with maintenance dialysis-clinical efficacy, risks and development of calciphylaxis
DK0804254T3 (da) Varmebehandling af blodplasmaproteiner
ME00015B (me) Preparat za kateter i njegova upotreba
ATE498305T1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
Chaves et al. Intramuscular administration of antivenoms in experimental envenomation by Bothrops asper: comparison between Fab and IgG
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
DE60021111D1 (de) Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln
JP2003286300A5 (ru)
WO2000068264A3 (en) A peptide inhibitor of fibrinogen blood clotting
ATE482705T1 (de) Antibakterielle behandlung von osteoarthritis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU